| Literature DB >> 31554827 |
Maryse Lessard1, Pauline M Herst1, Phanie L Charest1, Pauline Navarro2, Charles Joly-Beauparlant3, Arnaud Droit3, Sarah Kimmins4,5, Jacquetta Trasler6, Marie-Odile Benoit-Biancamano7, Amanda J MacFarlane8, Mathieu Dalvai1, Janice L Bailey9.
Abstract
The paternal environment is thought to influence sperm quality and future progeny may also be impacted. We hypothesized that prenatal exposure to environmentally-relevant contaminants impairs male reproduction, altering embryo gene expression over multiple generations. Folic acid (FA) can improve sperm quality and pregnancy outcomes, thus we further hypothesized that FA mitigates the contaminants. Sprague-Dawley F0 female rats treated with persistent organic pollutants (POPs) or corn oil and fed basal or supplemented FA diets, then used to yield four generations of litters. Only F0 females received POPs and/or FA treatments. In utero POPs exposure altered sperm parameters in F1, which were partly rescued by FA supplementation. Paternal exposure to POPs reduced sperm quality in F2 males, and the fertility of F3 males was modified by both POPs and FA. Ancestral FA supplementation improved sperm parameters of F4 males, while the POPs effect diminished. Intriguingly, F3 males had the poorest pregnancy outcomes and generated the embryos with the most significantly differentially expressed genes. Early-life exposure to POPs harms male reproduction across multiple generations. FA supplementation partly mitigated the impact of POPs. The two-cell embryo transcriptome is susceptible to paternal environment and could be the foundation for later pregnancy outcomes.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31554827 PMCID: PMC6761122 DOI: 10.1038/s41598-019-50060-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Sperm characteristics.
| ( | Testicular spermatid count (x106 ± SEM) | Sperm morphology (% ± SEM) | Sperm viability (% ± SEM) | |
|---|---|---|---|---|
|
| ||||
| CTRL | 74.32 ± 6.5 | 73.85 ± 3.8 | 92 ± 2 | 48a ± 3 |
| POPs | 70.68 ± 6.1 | 70.44 ± 4.0 | 90 ± 2 | 34b ± 3 |
| FA | 71.83 ± 6.1 | 74.91 ± 3.8 | 91 ± 2 | 45a ± 3 |
| POPsFA | 69.50 ± 6.5 | 71.71 ± 4.0 | 88 ± 2 | 44a ± 3 |
| POPs ( | POPs ( | POPs ( | POPs ( | |
| FA ( | FA ( | FA ( | FA ( | |
| POPs*FA ( | POPs*FA ( | POPs*FA ( |
| |
|
| ||||
| CTRL | 80.04a ± 6.2 | 82.42 ± 5.8 | 96a ± 1 | 39a ± 2 |
| POPs | 63.60b ± 5.6 | 65.14 ± 6.7 | 95a ± 1 | 30b ± 2 |
| FA | 78.40a ± 6.2 | 76.43 ± 5.8 | 93b ± 1 | 39a ± 2 |
| POPsFA | 57.24b ± 7.7 | 76.98 ± 6.0 | 96a ± 1 | 35b ± 2 |
| POPs ( | POPs ( | POPs ( | POPs ( | |
| FA ( | FA ( | FA ( | FA ( | |
| POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | |
|
| ||||
| CTRL | 66.39 ± 12.1 | 110.41 ± 10.9 | 92 ± 2 | 37a ± 3 |
| POPs | 47.75 ± 12.6 | 103.77 ± 10.9 | 93 ± 2 | 29a ± 3 |
| FA | 46.16 ± 10.6 | 109.48 ± 10.9 | 91 ± 2 | 39b ± 3 |
| POPsFA | 57.11 ± 10.7 | 105.03 ± 10.9 | 91 ± 2 | 39b ± 3 |
| POPs ( | POPs ( | POPs ( | POPs ( | |
| FA ( | FA ( | FA ( | ||
| POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | |
|
| ||||
| CTRL | 71.85 ± 11.0 | 111.72 ± 9.0 | 94 ± 1 | 57 ± 3 |
| POPs | 62.67 ± 11.0 | 120.37 ± 9.0 | 92 ± 1 | 54 ± 3 |
| FA | 90.39 ± 11.0 | 120.29 ± 9.0 | 94 ± 1 | 53 ± 3 |
| POPsFA | 77.39 ± 10.9 | 135.26 ± 9.0 | 94 ± 1 | 54 ± 3 |
| POPs ( | POPs ( | POPs ( | POPs ( | |
| FA ( | FA ( | FA ( | FA ( | |
| POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | |
Testicular spermatid counts in F1-F4 generation. F1 to F4 rat spermatozoa concentration (cauda epididymal sperm count normalized by epididymal weight). F1–F4 rat spermatozoa morphology. F1 to F4 rat spermatozoa viability. SEM = standard error of the mean.
Sperm motility parameters in F1-F4 generations.
| Total motility (%) ± SEM | Progressive motility (%) ± SEM | VAP (µm/s) ± SEM | VSL (µm/s) ± SEM | VCL (µm/s) ± SEM | ALH (µm/s) ± SEM | BCF (Hz) ± SEM | STR (%) ± SEM | LIN (%) ± SEM | |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| CTRL | 78a ± 6 | 67a ± 5 | 326.7 ± 18 | 243.6 ± 16 | 504.9 ± 23 | 20.1 ± 0.5 | 15.9 ± 0.9 | 67a ± 1 | 46a ± 1 |
| POPs | 64b ± 6 | 53b ± 5 | 282.9 ± 18 | 204.6 ± 16 | 454.6 ± 23 | 19.5 ± 0.5 | 17.7 ± 0.9 | 65b ± 1 | 42b ± 1 |
| FA | 82a ± 6 | 70a ± 5 | 316.0 ± 18 | 228.8 ± 16 | 503.3 ± 23 | 20.8 ± 0.5 | 17.2 ± 0.9 | 65b ± 1 | 42b ± 1 |
| POPsFA | 72b ± 6 | 61b ± 5 | 308.4 ± 18 | 227.4 ± 16 | 485.0 ± 23 | 20.0 ± 0.5 | 16.9 ± 0.9 | 66a ± 1 | 45a ± 1 |
| POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | |||
| FA ( | FA ( | FA ( | FA ( | FA ( | FA ( | FA ( | FA ( | FA ( | |
| POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | |||
|
| |||||||||
| CTRL | 52 ± 7 | 43 ± 6 | 212.5 ± 9 | 159.3 ± 8 | 319.6 ± 12 | 13.7 ± 0 | 14.9 ± 0.9 | 68a ± 1 | 47a ± 2 |
| POPs | 42 ± 8 | 32 ± 7 | 207.7 ± 11 | 164.4 ± 10 | 299.1 ± 13 | 12.5 ± 1 | 14.8 ± 1.0 | 70a ± 1 | 50a ± 2 |
| FA | 56 ± 7 | 42 ± 6 | 207.7 ± 9 | 151.0 ± 8 | 307.0 ± 12 | 13.3 ± 0 | 14.6 ± 0.9 | 66b ± 1 | 44b ± 2 |
| POPsFA | 53 ± 8 | 41 ± 6 | 189.1 ± 10 | 139.9 ± 9 | 286.7 ± 12 | 12.6 ± 1 | 15.7 ± 0.9 | 66b ± 1 | 45b ± 2 |
| POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | |
| FA ( | FA ( | FA ( | FA ( | FA ( | FA ( | FA ( | |||
| POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | |
|
| |||||||||
| CTRL | 48 ± 7 | 37 ± 5 | 241.2 ± 10 | 173.7 ± 8 | 398.2 ± 17 | 18.6 ± 7 | 19.4 ± 0.7 | 64a ± 1 | 41 ± 1 |
| POPs | 46 ± 7 | 34 ± 6 | 227.5 ± 10 | 151.0 ± 8 | 370.3 ± 17 | 18.0 ± 7 | 20.3 ± 0.7 | 61b ± 1 | 40 ± 1 |
| FA | 44 ± 7 | 34 ± 6 | 237.7 ± 10 | 161.6 ± 8 | 387.8 ± 17 | 32.4 ± 7 | 20.1 ± 0.7 | 62a ± 1 | 41 ± 1 |
| POPsFA | 52 ± 7 | 39 ± 6 | 242.2 ± 10 | 163.7 ± 8 | 397.5 ± 17 | 18.1 ± 7 | 20.4 ± 0.7 | 61b ± 1 | 40 ± 1 |
| POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | ||
| FA ( | FA ( | FA ( | FA ( | FA ( | FA ( | FA ( | FA ( | FA ( | |
| POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | |
|
| |||||||||
| CTRL | 56 ± 6 | 43 ± 5 | 221.0 ± 21 | 146.6a ± 20 | 349.0a ± 23 | 16.8 ± 1 | 18.9 ± 0.9 | 64 ± 1 | 43 ± 1 |
| POPs | 57 ± 6 | 45 ± 5 | 231.6 ± 21 | 167.1a ± 20 | 350.2a ± 23 | 15.7 ± 1 | 18.5 ± 0.9 | 66 ± 1 | 46 ± 1 |
| FA | 65 ± 6 | 52 ± 5 | 250.9 ± 21 | 184.7b ± 20 | 385.6b ± 23 | 16.9 ± 1 | 17.4 ± 0.9 | 66 ± 1 | 45 ± 1 |
| POPsFA | 58 ± 6 | 45 ± 5 | 279.9 ± 21 | 219.3b ± 21 | 409.3b ± 23 | 16.1 ± 1 | 17.5 ± 0.9 | 68 ± 1 | 47 ± 1 |
| POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | |
| FA ( | FA ( | FA ( | FA ( | FA ( | FA ( | FA ( | |||
| POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | |
(VAP: Average path velocity; VSL: Linear velocity; VCL: Curvilinear velocity; ALH: mean amplitude of lateral head displacement; BCF: frequency of head displacement; STR: straightness coefficient; LIN: linearity coefficient). SEM = standard error of the mean.
Figure 1Differential gene expression in two-cell embryos due to prenatal paternal POPs, FA and POPsFA exposure. (A) Venn diagrams comparing the number of significantly differentially expressed genes due to POPs, FA and POPsFA in F2-F4 two-cell embryos. (B) Table including total number of significantly expressed (Sig. exp.) genes (p value ≤ 0.05, FDR ≤5%) and the number of significantly differentially expressed (Sig. DE) genes (p value ≤ 0.05, FDR ≤5% and −2≥ |Log2 Fold change| ≥2) that are up- or downregulated indicated by ↑ and ↓ respectively due to POPs, FA and POPsFA in F2-F4. (C) Gene ontology (GO) and pathway analysis showing only significantly affected pathways (p value ≤ 0.05). (D) Heatmaps representing common genes shared between all treatments per generation. (E) Candidate genes that are altered across multiple generations due to POPs, FA and POPsFA across F2-F4.
Pregnancy outcomes for F1-F3 fathers.
| Nb fetuses | Implantation sites | Fertility rate (% ± SEM) | Preimplantation losses (% ± SEM) | Postimplantation losses (% ± SEM) | Neonatal deaths (% ± SEM) | |
|---|---|---|---|---|---|---|
|
| ||||||
| CTRL | 12 ± 1 | 13 ± 1 | 85 ± 7 | 11 ± 4 | 4 ± 8 | 18 ± 12 |
| POPs | 13 ± 1 | 14 ± 1 | 85 ± 7 | 10 ± 4 | 6 ± 7 | 20 ± 13 |
| FA | 14 ± 1 | 14 ± 1 | 90 ± 7 | 9 ± 4 | 1 ± 7 | 1 ± 13 |
| POPsFA | 11 ± 1 | 13 ± 1 | 82 ± 7 | 6 ± 4 | 16 ± 7 | 2 ± 12 |
| POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | |
| FA ( | FA ( | FA ( | FA ( | FA ( | FA ( | |
| POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | |
|
| ||||||
| CTRL | 12 ± 2 | 12 ± 2 | 85 ± 13 | 8 ± 13 | 7 ± 3 | 10 ± 5 |
| POPs | 14 ± 2 | 15 ± 2 | 89 ± 15 | 6 ± 15 | 4 ± 3 | 6 ± 5 |
| FA | 10 ± 2 | 10 ± 2 | 68 ± 13 | 30 ± 13 | 3 ± 3 | 2 ± 5 |
| POPsFA | 12 ± 2 | 12 ± 2 | 96 ± 15 | 1 ± 15 | 5 ± 3 | 1 ± 5 |
| POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | POPs ( | |
| FA ( | FA ( | FA ( | FA ( | FA ( | FA ( | |
| POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | |
|
| ||||||
| CTRL | 14a ± 1 | 14a ± 1 | 84a ± 8 | 14a ± 7 | 2a ± 6 | 11.3 ± 9 |
| POPs | 12b ± 1 | 13b ± 1 | 88a ± 8 | 11a ± 7 | 1a ± 6 | 1.3 ± 8 |
| FA | 13a ± 1 | 14a ± 1 | 89a ± 8 | 5a ± 7 | 6b ± 6 | 3.6 ± 9 |
| POPsFA | 9b ± 1 | 11b ± 1 | 54b ± 8 | 33b ± 7 | 24b ± 6 | 15.6 ± 8 |
| POPs ( | POPs ( | POPs ( | POPs ( | |||
| FA ( | FA ( | FA ( | FA ( | FA ( | ||
| POPs*FA ( | POPs*FA ( | POPs*FA ( | POPs*FA ( | |||
Fertility rate corresponds to (# fetuses/# corpus lutea)*100, pre-implantation losses corresponds to ((# corpus lutea – # implantation sites)/# corpus lutea)*100 and post-implantation losses corresponds to ((# implantation sites - # fetuses)/# implantation sites)*100. Neonatal deaths correspond to pups dead after birth during the first week of life (PND 1 to PND 6).
Composition of POPs mixture used[25,63].
| Products | CAS no. | Origina | % in mixture | Dose (µg/kg body weight) |
|---|---|---|---|---|
| Aroclor and congener neat mixb | AccuStandard | 32.4 | 500 | |
| Technical chlordane | 57-74-9 | AccuStandard | 21.4 | 330.3 |
| Dichlorodiphenyldichloroethylene | 72-55-9 | Sigma-Aldrich | 19.3 | 297.8 |
| Dichlorodiphenyltrichloroethane ( | 50-29-3 | SigmaAldrich | 6.8 | 104.9 |
| Technical toxaphene | 8001-35-2 | AccuStandard | 6.5 | 100.0 |
| 319-84-6 | Sigma-Aldrich | 6.2 | 95.7 | |
| Aldrin | 309-00-2 | Sigma-Aldrich | 2.5 | 38.6 |
| Dieldrin | 60-57-1 | Sigma-Aldrich | 2.1 | 32.4 |
| 1,2,4,5-tetrachlorobenzene | 95-94-3 | Sigma-Aldrich | 0.9 | 13.9 |
| Dichlorodiphenyldichloroethane ( | 72-54-8 | Sigma-Aldrich | 0.5 | 7.7 |
| 319-85-7 | Sigma-Aldrich | 0.4 | 6.2 | |
| Hexachlorobenzene | 118-74-1 | AccuStandard | 0.4 | 6.2 |
| Mirex | 2385-85-5 | Sigma-Aldrich | 0.2 | 3.1 |
| Lindane | 58-89-9 | Sigma-Aldrich | 0.2 | 3.1 |
| Pentachlorobenzene | 608-93-5 | Sigma-Aldrich | 0.2 | 3.1 |
aAccuStandard Inc (New Haven, Connecticut); Sigma-Aldrich Inc (St Louis, Missouri).
bMix containing PCBs: Aroclor 1260 (58.9%); Aroclor 1254 (39.3%); 2,4,4′-trichlorobiphenyl (PCB 28; 1%); 2,2′,4,4′-tetrachlorobiphenyl (PCB 47; 0.8%); 3,3′,4,4′,5-pentachlorobiphenyl (PCB 126; 0.02%), and 3,3′,4,4′-tetrachlorobiphenyl (PCB 77; 0.004%).
Figure 2Study design. Four treatment groups of Sprague-Dawley F0 founder females (n = 6) were gavaged with an environmentally-relevant POPs mixture or corn oil and received either a control diet (2 mg FA/kg diet) or supplemented diet (6 mg FA/kg diet). F0 females were treated for 5 weeks and then mated to untreated males; POPs and FA supplementation treatments continued until the birth of the F1 litters. Only F0 females received POPs or supplemented FA diet.